Trial Profile
Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SURF
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
- 17 Nov 2021 Planned primary completion date changed from 30 Mar 2021 to 1 Feb 2024.